MSTO-211H
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
MSTO-211H |
Humane Lunge Mesotheliom Zell-Linie |
300450 |
cryovial |
265,00 |
MSTO-211H |
Humane Lunge Mesotheliom Zell-Linie |
330450 |
vital |
335,00 |
| Designation: | MSTO-211H |
| Depositor: | Bepler |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 62 years |
| Gender: | male |
| Tissue: | mesothelioma, biphasic; from metastatic site: lung |
| Morphology: | fibroblast |
| Growth Properties: | adherent |
| Description: | The MSTO-211H cell line was established in 1985 from the pleural effusion of a patient with biphasic mesothelioma of the lung. The patient had not received prior radiation or chemotherapy. MSTO-211H cells have high affinity binding sites for EGF and express Neuron specific enolase (NSE) as well as the alpha and beta subunits of human chorionic gonadotropin (HCG). L-DOPA decarboxylase (DDC), bombesin and neurotensin were not detected. The cells overexpress the c-myc protooncogene, and no gene rearrangement or amplification was observed. |
| Culture Medium: | RPMI 1640 medium supplemented with 2 mM L-glutamine, and 10% fetal bovine serum. |
| Subculturing: | The cells can reach a saturation density of 400000 cells per cm2, but will slough off the surface as they attain this density. Remove spent medium, add fresh 0.025% trypsin, 0.03% EDTA solution, rinse and remove trypsin. Add fresh trypsin, and let the culture sit at room temperature (or at 37°C) until the cells detach. Add fresh medium, aspirate and dispense into new flasks. |
| Split Ratio: | A ratio of 1:3 to 1:6 is recommended |
| Fluid Renewal: | every 2 to 3 days |
| Doubling Time: | 20 hrs |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, tumors for med in approximately 20% of nude mice inoculated with MSTO-211H cells |
| Oncogene: | c-myc ; v-src +; v-abl +; v-erb B +; c-raf 1 +; Ha-ras +; Ki-ras +; N-ras +; N-myc -; L-myc - c-myb -; c-fos -; v-fes -; v-fms -; v-sis - |
| Karyotype: | modal number = 72; range = 70 to 78 |
| DNA Profile (STR): | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11,14 D16S539: 13 D5S818: 12 D7S820: 8,12 THO1: 8,9.3 TPOX: 11 vWA: 16,18 D3S1358: 15 D21S11: 28,31 D18S51: 16,18 Penta E: 7,13 Penta D: 11,12 D8S1179: 13 FGA: 21 CLS ∙ Cell Lines Service, 2009. |
References: Bepler G et al. Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37: 158-71, 1988. Haeder M et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 48: 1132-1136, 1988. Bepler G and Koehler A. Multiple chromosomal aberrations and 11p allelotyping in lung cancer cell lines. Cancer Genet Cytogenet 84: 39-45, 1995. Hofmann J et al. Glucocorticoid receptors and growth inhibitory effects of dexamethasone in human lung cancer cell lines. Eur J Cancer 31A: 2053-8, 1995. Suzuki R et al. MCI-186 inhibits tumor growth through suppression of EGFR phosphorylation and cell cycle arrest. Anticancer Res 25: 1131-8, 2005. Adusumilli PS et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 5: 48-53, 2006. Zeold A et al. Characterization of the nuclear factor-kappa B responsiveness of the human dio2 gene. Endocrinology 147: 4419-29, 2006. | |
